tert-butyl (3-bromo-2,6-difluorophenyl)carbamate | 721446-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (3-bromo-2,6-difluorophenyl)carbamate
• 英文别名: tert-butyl N-(3-bromo-2,6-difluorophenyl)carbamate
• CAS: 721446-29-3
• 化学式: C₁₁H₁₂BrF₂NO₂
• 分子量: 308.123
• InChiKey: GFFALKCIACMPPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3-bromo-2,6-difluorophenyl)carbamate 、 三氟乙酸 在 乙酸乙酯 、 水 、 Brine 、 Sodium sulfate-III 、 silica 、 SiO2 、 正庚烷 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以afforded 425 mg (63%) of 3-bromo-2,6-difluoroaniline的产率得到3-溴-2,6-二氟苯胺
  参考文献：
  名称：

  Compounds and Compositions as Protein Kinase Inhibitors

  摘要：

  本发明提供了式I或II的化合物：其中R1、R1b、R2、R3、R4、R5、R6和R7的定义如本文所述。式（I）或（II）的化合物及其制备的药物组合物对于治疗B-Raf相关疾病是有用的。

  公开号：

  US20140011825A1
• 作为产物：
  描述：

  3-溴-2,6-二氟苯甲酸 在 白碳黑 DIEA 、 DPPA 作用下， 以 正庚烷 、 乙酸乙酯 、 甲苯 、 叔丁醇 为溶剂， 以3.49 g (54%)的产率得到tert-butyl (3-bromo-2,6-difluorophenyl)carbamate
  参考文献：
  名称：

  Compounds and Compositions as Protein Kinase Inhibitors

  摘要：

  本发明提供了式I或II的化合物： 其中R1、R1b、R2、R3、R4、R5、R6和R7在此处定义。式(I)或(II)的化合物及其药物组合物对于治疗B-Raf相关疾病是有用的。

  公开号：

  US20110052578A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：IRM LLC

  公开号：WO2011025927A1

  公开（公告）日：2011-03-03

  The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

  这项发明提供了一类新型的化合物，其化学式为1，包括这些化合物的药物组合物以及使用这些化合物来治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法，特别是涉及B-Raf异常激活的疾病或障碍。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Huang Shenlin

  公开号：US20110306625A1

  公开（公告）日：2011-12-15

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

  本发明提供了一类新型化合物，包括这些化合物的药物组成物，以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或疾病的方法，特别是涉及B-Raf异常活化的疾病或疾病的方法。
• Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors
  作者：Kenichi Onda、Ryota Shiraki、Takashi Ogiyama、Kazuhiro Yokoyama、Kazuhiro Momose、Naoko Katayama、Masaya Orita、Tomohiko Yamaguchi、Masako Furutani、Noritaka Hamada、Makoto Takeuchi、Minoru Okada、Mitsuaki Ohta、Shin-ichi Tsukamoto

  DOI：10.1016/j.bmc.2008.10.021

  日期：2008.12

  As a result of the various N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives with a hydroxy moiety synthesized in an effort to discover novel glycogen phosphorylase (GP) inhibitors, 5-chloro-N-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-indole-2-carboxamide (5b) was found to have potent inhibitory activity. The introduction of fluorine atoms both at a position adjacent to the hydroxy group and in the central benzene moiety lead to the optically active derivative 5-chloro-N-[(5R)-1,3,6,6-tetrafluoro-5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl]-1H-indole-2-carboxamide(25e alpha, which was the most potent compound in this series (IC(50) = 0.020 mu M). This compound inhibited glucagon-induced glucose output in cultured primary hepatocytes with an IC(50) value of 0.69 mu M, and showed oral hypoglycemic activity in diabetic db/db mice at 10 mg/kg. Compound 25e alpha also had an excellent pharmacokinetic profile, with high oral bioavailability and a long plasma half-life, in male SD rats. The binding mode of 25e alpha to this molecule and the role of fluorine atoms in that binding were speculated in an enzyme docking study. (c) 2008 Elsevier Ltd. All rights reserved.
• EP2727918A1
  申请人：——

  公开号：EP2727918A1

  公开（公告）日：2014-05-07
• Compounds And Compositions As Protein Kinase Inhibitors
  申请人：Array BioPharma Inc.

  公开号：US20200323852A1

  公开（公告）日：2020-10-15

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.